GO:0032307 negative regulation of prostaglandin secretion: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032307 describes any process that stops, prevents, or reduces the regulated release of a prostaglandin from a cell, including prostacyclin (PGI2).
• Prostaglandin secretion is controlled at the level of cyclooxygenase (COX) enzymes, terminal prostaglandin synthases, and prostaglandin transporters, so negative regulation can act at synthesis, transport, or signaling steps.
• Macrophage efferocytosis suppresses prostaglandin output through apoptotic cell-derived methionine and DNMT3A-dependent epigenetic remodeling, a physiological example of negative regulation.
• PGE2 accumulation restrains T cell expansion by disrupting IL-2 signaling and mitochondrial function, so negative regulation of prostaglandin secretion is critical for effective antitumor immunity.
• In sepsis and neuroinflammation, failure to restrain prostaglandin secretion contributes to blood-brain barrier disruption and hyperinflammation.
• CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal testing of candidate negative regulators of prostaglandin secretion in relevant cell types.
Description
GO:0032307, negative regulation of prostaglandin secretion, is a biological process term in the Gene Ontology that covers any mechanism that stops, prevents, or reduces the frequency, rate, or extent of regulated prostaglandin release from a cell. Prostaglandins are lipid mediators generated from arachidonic acid by cyclooxygenase (COX) and terminal synthase enzymes, and their secretion is tightly controlled because excessive or prolonged release drives inflammation, pain, fever, and immune suppression. Understanding the negative arm of this control is essential for interpreting how tissues resolve inflammation and return to homeostasis. Experimental work in macrophages has shown that efferocytosis of apoptotic cells reprograms prostaglandin metabolism and suppresses pro-inflammatory mediator output, providing a direct physiological example of negative regulation of prostaglandin secretion. In parallel, studies of T cell biology demonstrate that when prostaglandin E2 (PGE2) secretion is not adequately restrained, IL-2 signaling and mitochondrial function in tumor-infiltrating lymphocytes are disrupted, limiting antitumor immunity. These findings place GO:0032307 at the intersection of immunometabolism, vascular biology, and endocrine regulation. Researchers studying inflammation resolution, sepsis, cancer immunology, and neurovascular disease therefore need reliable models to test which genes causally restrain prostaglandin release.
negative regulation of prostaglandin secretion At A Glance
| GO ID | GO:0032307 |
|---|---|
| GO term | negative regulation of prostaglandin secretion |
| Ontology | biological_process |
| Synonym | down regulation of prostaglandin secretion; down-regulation of prostaglandin secretion; downregulation of prostaglandin secretion; inhibition of prostaglandin secretion; negative regulation of prostacyclin secretion |
| Major function | Reduces the frequency, rate, or extent of regulated prostaglandin release from a cell |
| Representative mediators | COX-2 (PTGS2), terminal prostaglandin synthases, prostaglandin transporters, and efferocytosis-associated epigenetic regulators such as DNMT3A |
| Physiological context | Inflammation resolution, immune cell function, vascular tone, and endocrine signaling |
| Disease relevance | Sepsis-associated encephalopathy, tumor immune evasion, and hyperinflammatory states |
| Experimental readouts | Secreted PGE2/PGF2alpha measurement, COX-2 expression, transporter activity, and immune cell functional assays |
What Is GO:0032307?
In practical terms, GO:0032307 refers to any cellular process that reduces the amount of prostaglandin released from a cell. The official Gene Ontology definition states: any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of a prostaglandin from a cell. This includes negative regulation of prostacyclin (PGI2) secretion, and it can be achieved by limiting substrate availability, inhibiting COX or terminal synthase activity, altering prostaglandin transport, or changing the expression of enzymes and transporters involved in prostaglandin production and export. Because the term is defined at the level of regulated release, it is distinct from terms describing prostaglandin synthesis alone; a gene product annotated to GO:0032307 must measurably reduce the secreted prostaglandin pool, not merely change intracellular lipid levels.
Why Is negative regulation of prostaglandin secretion Important in Cell Biology?
Negative regulation of prostaglandin secretion is important because prostaglandins are potent local mediators whose uncontrolled release amplifies inflammation, suppresses antitumor immunity, and disrupts vascular and endocrine function. When this negative control fails, PGE2 can accumulate in the tumor microenvironment and impair IL-2 signaling and mitochondrial function in tumor-infiltrating lymphocytes, reducing the effectiveness of immune responses. In sepsis, dysregulated prostaglandin and lipid mediator production is linked to blood-brain barrier disruption and hyperinflammation, making the negative regulatory arm a potential therapeutic target. In endocrine tissues such as the adrenal gland and pancreatic islets, prostaglandin synthesis and secretion are subject to dominant regulatory inputs, including COX-2, that shape hormone output. Thus, genes and pathways annotated to GO:0032307 are central to understanding how tissues switch from active inflammation to resolution and how this switch can be restored or reinforced experimentally.
• Controls the magnitude and duration of inflammatory prostaglandin release, which determines whether inflammation resolves or becomes chronic.
• Restrains PGE2 accumulation in tumors, thereby preserving IL-2 signaling and mitochondrial fitness in T cells.
• Protects the blood-brain barrier during sepsis-associated encephalopathy by limiting prostaglandin-driven neuroinflammation.
• Shapes adrenal endocrine output, where prostaglandin F2alpha and aldo-keto reductase 1B7 participate in steroidogenic regulation.
• Contributes to cerebral blood flow regulation through astrocyte-mediated prostaglandin signaling.
• Modulates cell proliferation through positive and negative prostaglandin receptor signaling in fibroblasts.
• Limits hyperinflammation in sepsis through macrophage metabolic reprogramming and lipid mediator control.
• Provides a mechanistic explanation for why COX-2 dominance in pancreatic islets must be counterbalanced to avoid excessive prostaglandin synthesis.
• Offers druggable nodes (COX-2, synthases, transporters, epigenetic regulators) for anti-inflammatory and immuno-oncology strategies.
• Enables causal gene discovery when combined with CRISPR knockout, point-mutation, knock-in, and overexpression models.
What Happens During negative regulation of prostaglandin secretion?
Reduced substrate availability and COX-2 suppression
In simple terms: The cell makes less raw material for prostaglandins or turns down the first enzyme in the assembly line.
Prostaglandin secretion begins with arachidonic acid release and its conversion by cyclooxygenase enzymes, with COX-2 (PTGS2) often dominating in activated cells such as pancreatic islets. Negative regulation of prostaglandin secretion can therefore be achieved by reducing arachidonic acid availability or by suppressing COX-2 expression or activity, which lowers the pool of prostaglandin intermediates available for release. In macrophages, efferocytosis of apoptotic cells reprograms this axis and suppresses pro-inflammatory mediator output, illustrating how substrate and enzyme control converge to reduce prostaglandin secretion.
Epigenetic reprogramming during efferocytosis
In simple terms: When macrophages eat dying cells, they rewrite chemical marks on DNA that quiet prostaglandin-producing genes.
Apoptotic cell-derived methionine and DNMT3A mediate epigenetic changes in macrophages during efferocytosis, promoting a tissue-resolution program that includes reduced secretion of pro-inflammatory prostaglandins. This demonstrates that negative regulation of prostaglandin secretion is not only a rapid enzymatic event but can also be installed through DNA methylation-dependent transcriptional remodeling. The consequence is a sustained shift toward resolution rather than a transient blockade of release.
Transport and export control
In simple terms: Even if prostaglandins are made, the cell can hold them inside by limiting the doors that let them out.
Because GO:0032307 is defined at the level of regulated release, control of prostaglandin transport out of the cell is a core mechanism. Reducing the activity or expression of prostaglandin transporters lowers the secreted pool without necessarily changing intracellular synthesis rates. This distinction matters experimentally, because measuring only intracellular prostaglandin levels can miss a transport-mediated negative regulatory event.
Feedback from prostaglandin receptors
In simple terms: Prostaglandin signals can loop back and tell the cell to stop releasing more prostaglandin.
Prostaglandin receptors can mediate both positive and negative regulation of cell proliferation in NIH-3T3 cells, showing that receptor-coupled feedback can restrain prostaglandin-driven outputs. Such feedback provides a self-limiting mechanism that contributes to negative regulation of prostaglandin secretion at the level of the secreting cell. This receptor-level control is relevant when interpreting why some cells stop releasing prostaglandins after an initial burst.
Metabolic and immune consequences of failed negative regulation
In simple terms: If the brake fails, too much prostaglandin spills out and disrupts immune and vascular cells.
When negative regulation of prostaglandin secretion is insufficient, PGE2 accumulates and inhibits TIL expansion by disrupting IL-2 signaling and mitochondrial function. In sepsis models, prostaglandin and lipid mediator dysregulation is associated with blood-brain barrier disruption and hyperinflammation. These outcomes show that GO:0032307 is functionally coupled to immune competence and vascular integrity, not merely to lipid metabolism.
Key Genes Involved in GO:0032307 negative regulation of prostaglandin secretion
The following genes and proteins are experimentally linked to prostaglandin synthesis, secretion, or its negative regulation in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTGS2 (COX-2) | Rate-limiting cyclooxygenase for prostaglandin synthesis; dominant in pancreatic islets | Knockout or point-mutation models test whether COX-2 suppression is required for negative regulation of prostaglandin secretion |
| DNMT3A | DNA methyltransferase mediating efferocytosis-associated epigenetic reprogramming | Knockout macrophages test whether DNMT3A is required for suppression of prostaglandin secretion during resolution |
| Methionine metabolism genes (efferocytosis axis) | Supply methyl donors for DNMT3A-dependent methylation | Overexpression or knockout models test substrate dependence of negative regulation |
| Prostaglandin E2 (PGE2) pathway genes | Produce the PGE2 that restrains TIL expansion | Knock-in reporter models quantify secreted PGE2 in tumor immune contexts |
| Poldip2 | Mediates blood-brain barrier disruption in sepsis-associated encephalopathy | Knockout models test whether Poldip2 loss restores barrier integrity via prostaglandin control |
| Aldo-keto reductase 1B7 (AKR1B7) | Regulates adrenal endocrine function with prostaglandin F2alpha | Knockout or overexpression models test adrenal prostaglandin output |
| Prostaglandin F2alpha (PGF2alpha) pathway genes | Terminal prostaglandin that regulates adrenal endocrine functions | Point-mutation models test synthase activity and secretion |
| Astrocyte prostaglandin pathway genes | Regulate cerebral blood flow in health and disease | Cell-type-specific knockout models test neurovascular coupling |
| Prostaglandin receptors (e.g., EP receptors) | Mediate positive and negative regulation of cell proliferation | Knockout and knock-in models dissect receptor-specific feedback |
| DPEP2 | Suppresses hyperinflammation via macrophage metabolic reprogramming in sepsis | Knockout models test whether DPEP2 loss increases prostaglandin secretion |
| COX-2 regulatory network in islets | Dominant control of pancreatic islet prostaglandin synthesis | Islet-specific knockout models test endocrine prostaglandin secretion |
| Prostaglandin transporters | Control regulated release of prostaglandins from cells | Transport assays and knockout models distinguish synthesis from secretion |
| IL-2 signaling components | Downstream targets of PGE2-mediated suppression in TILs | Functional assays in knockout T cells test rescue by prostaglandin blockade |
| Mitochondrial function genes in TILs | Affected by PGE2 accumulation | Seahorse and knockout models test metabolic rescue |
| Sepsis-associated lipid mediator genes | Linked to hyperinflammation and barrier disruption | Knockout and knock-in models test mediator-specific effects |
| Efferocytosis receptors | Initiate the resolution program that suppresses prostaglandin secretion | Knockout macrophages test upstream control of GO:0032307 |
How Is negative regulation of prostaglandin secretion Regulated?
Negative regulation of prostaglandin secretion is itself regulated at multiple levels. During efferocytosis, apoptotic cell-derived methionine feeds DNMT3A-dependent DNA methylation that installs a resolution program and suppresses prostaglandin output. COX-2 dominance in pancreatic islets indicates that transcriptional control of the synthetic enzyme is a major determinant of how much prostaglandin can be secreted. Prostaglandin receptor signaling can feed back to limit cell proliferation and likely secretion, providing a self-restraining loop. In sepsis, macrophage metabolic reprogramming involving DPEP2 restrains hyperinflammation, indirectly constraining prostaglandin-driven pathology. Finally, PGE2 accumulation in tumors suppresses IL-2 signaling and mitochondrial function, creating a feedback environment in which restoring negative regulation of prostaglandin secretion could re-enable immune expansion.
negative regulation of prostaglandin secretion and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTGS2 (COX-2) | Pancreatic islet prostaglandin synthesis and endocrine dysfunction | Islet-specific knockout and point-mutation models |
| DNMT3A | Inflammation resolution failure and chronic inflammation | Macrophage knockout and knock-in models |
| Poldip2 | Sepsis-associated encephalopathy and blood-brain barrier disruption | Endothelial or astrocyte knockout models |
| DPEP2 | Sepsis hyperinflammation | Macrophage knockout and overexpression models |
| PGE2 pathway genes | Tumor immune evasion and TIL dysfunction | Tumor and T cell co-culture knockout models |
Cancer immune evasion
PGE2 inhibits TIL expansion by disrupting IL-2 signaling and mitochondrial function, so tumors that fail to restrain prostaglandin secretion can evade immune control. Negative regulation of prostaglandin secretion is therefore a determinant of immunotherapy responsiveness, and genes annotated to GO:0032307 are candidate targets for restoring T cell fitness.
Sepsis-associated encephalopathy and hyperinflammation
Poldip2 mediates blood-brain barrier disruption in a model of sepsis-associated encephalopathy, linking prostaglandin-related neuroinflammation to barrier failure. DPEP2 suppresses hyperinflammation via macrophage metabolic reprogramming in sepsis, indicating that loss of negative control over lipid mediators worsens outcomes. Together these studies position GO:0032307 as a protective process in systemic inflammation.
Endocrine and metabolic disorders
Aldo-keto reductase 1B7 and prostaglandin F2alpha regulate adrenal endocrine functions, showing that prostaglandin secretion control is embedded in steroidogenic physiology. In pancreatic islets, COX-2 dominates prostaglandin synthesis, so dysregulated negative regulation could alter islet hormone output. These findings connect GO:0032307 to endocrine and metabolic disease research.
Neurovascular disease
Astrocytes regulate cerebral blood flow in health and disease through prostaglandin-dependent signaling. When negative regulation of prostaglandin secretion is impaired, neurovascular coupling and barrier function may be compromised, as seen in sepsis-associated encephalopathy models. This makes GO:0032307 relevant to stroke, neuroinflammation, and vascular cognitive impairment research.
From negative regulation of prostaglandin secretion-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required to suppress prostaglandin secretion? | CRISPR knockout in macrophages or relevant cell type with secreted PGE2 measurement |
| Does a specific enzyme residue control prostaglandin output? | Point-mutation knock-in of catalytic or regulatory residues |
| Can a resolution program be installed epigenetically? | Knock-in of methylation-sensitive reporters or DNMT3A variants |
| Does overexpression of a negative regulator reduce prostaglandin secretion? | Doxycycline-inducible overexpression cell line |
| Which transporters control regulated release? | Tagged knock-in of transporter genes plus secretion assays |
| Does prostaglandin restraint rescue T cell function? | Knockout T cells co-cultured with tumor cells and IL-2 signaling readouts |
How to Study the negative regulation of prostaglandin secretion Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ELISA for PGE2/PGF2alpha | Secreted prostaglandin concentration | Quantifying negative regulation of prostaglandin secretion |
| LC-MS lipid mediator profiling | Panel of prostaglandins and related lipids | Macrophage and sepsis hyperinflammation studies |
| RNA-seq | Transcriptional changes in COX-2 and synthases | Efferocytosis and islet prostaglandin programs |
| DNA methylation profiling | DNMT3A-dependent epigenetic marks | Resolution program installation |
| Seahorse mitochondrial assay | Mitochondrial function in TILs | PGE2-mediated T cell suppression |
| Blood-brain barrier permeability assay | Barrier integrity in sepsis models | Poldip2 and neuroinflammation studies |
| Cerebral blood flow imaging | Neurovascular coupling | Astrocyte prostaglandin signaling |
| Cell proliferation assay | Receptor-mediated growth control | Prostaglandin receptor feedback studies |
Measuring secreted prostaglandins
Quantifying PGE2, PGF2alpha, or PGI2 in conditioned medium is the direct readout for GO:0032307. Studies of TIL suppression by PGE2 and adrenal regulation by PGF2alpha illustrate how secreted lipid measurements are used to link gene function to prostaglandin release. Pairing secretion measurements with intracellular lipid quantification distinguishes transport-mediated negative regulation from synthesis inhibition.
Transcriptional and epigenetic profiling
RNA-seq and DNA methylation profiling reveal how efferocytosis-associated DNMT3A activity reprograms macrophages toward reduced prostaglandin secretion. COX-2 expression profiling in pancreatic islets shows how transcriptional dominance of a single synthase shapes prostaglandin output. These approaches identify candidate negative regulators for CRISPR validation.
Functional immune and vascular assays
IL-2 signaling and mitochondrial function assays in TILs measure the downstream consequences of PGE2 accumulation. Blood-brain barrier permeability assays in sepsis models measure the vascular consequences of failed prostaglandin restraint. Cerebral blood flow imaging in astrocyte models links prostaglandin signaling to neurovascular function.
Metabolic and lipid mediator profiling
Macrophage metabolic reprogramming studies in sepsis use lipid mediator profiling to show how DPEP2 restrains hyperinflammation. Such profiling can identify which prostaglandin species are most affected by a candidate negative regulator. Combining metabolomics with CRISPR perturbation provides causal evidence for GO:0032307 annotation.
How CRISPR Can Be Used to Study GO:0032307 negative regulation of prostaglandin secretion
Knockout
CRISPR knockout of candidate genes such as DNMT3A, PTGS2, or DPEP2 allows direct testing of whether loss of function increases secreted prostaglandins. Knockout macrophages and islet cells are particularly informative because these cell types have well-characterized prostaglandin outputs. A validated knockout that raises secreted PGE2 supports annotation of the target gene to GO:0032307.
Point Mutation
Point-mutation knock-in can dissect catalytic residues in COX-2 or terminal synthases and regulatory residues in transporters. Such models distinguish enzymatic control of prostaglandin synthesis from transport-mediated control of secretion. They are essential when a gene has multiple domains with separable functions.
Knock-in
Tagged knock-in of prostaglandin transporters or synthases enables tracking of protein localization and secretion dynamics. Reporter knock-in at prostaglandin-responsive loci can quantify pathway activity in live cells. These models help assign a gene to the regulated-release step of GO:0032307 rather than to upstream synthesis.
Overexpression
Overexpression of a candidate negative regulator, such as DPEP2 or a resolution-associated factor, tests whether increased dosage reduces prostaglandin secretion. Inducible overexpression systems allow dose- and time-dependent analysis of secretion suppression. Rescue experiments in knockout backgrounds confirm causality.
How EDITGENE Supports negative regulation of prostaglandin secretion Research
Researchers studying negative regulation of prostaglandin secretion-related genes often need to determine whether a candidate gene is causally involved in reducing prostaglandin release or is merely correlated with a resolution phenotype. Because GO:0032307 is defined at the level of regulated release, the strongest evidence comes from perturbing the candidate gene and measuring secreted prostaglandins directly. CRISPR-based models provide that causal link by removing, mutating, tagging, or overexpressing the gene of interest in relevant cell types such as macrophages, T cells, islet cells, and endothelial cells.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of prostaglandin secretion research.
Frequently Asked Questions About negative regulation of prostaglandin secretion
What is GO:0032307 negative regulation of prostaglandin secretion?
GO:0032307 is a Gene Ontology biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of the regulated release of a prostaglandin from a cell, including prostacyclin secretion.
What genes are involved in negative regulation of prostaglandin secretion?
Genes experimentally linked to this process include DNMT3A and methionine metabolism genes in efferocytosis, PTGS2 (COX-2) in islets, DPEP2 in sepsis macrophages, and prostaglandin receptor and transporter genes.
How is prostaglandin secretion negatively regulated during inflammation resolution?
During efferocytosis, apoptotic cell-derived methionine supports DNMT3A-dependent epigenetic reprogramming that suppresses pro-inflammatory prostaglandin output and promotes tissue resolution.
Why is negative regulation of prostaglandin secretion important in cancer?
PGE2 accumulation inhibits TIL expansion by disrupting IL-2 signaling and mitochondrial function, so restraining prostaglandin secretion supports antitumor immunity.
Which diseases are linked to failed negative regulation of prostaglandin secretion?
Sepsis-associated encephalopathy, hyperinflammation, tumor immune evasion, and endocrine dysfunction have been linked to dysregulated prostaglandin secretion.
What is the role of COX-2 in prostaglandin secretion?
COX-2 (PTGS2) is a rate-limiting cyclooxygenase that dominates prostaglandin synthesis in pancreatic islets, so its suppression reduces the prostaglandin pool available for secretion.
How do prostaglandin receptors feedback on secretion?
Prostaglandin receptors can mediate both positive and negative regulation of cell proliferation, providing a self-limiting feedback loop that can restrain prostaglandin-driven outputs.
What experimental models study negative regulation of prostaglandin secretion?
CRISPR knockout, point-mutation, knock-in, and overexpression cell models in macrophages, T cells, islet cells, and endothelial cells are used with secreted prostaglandin measurements.
Does Poldip2 affect prostaglandin-related blood-brain barrier disruption?
Poldip2 mediates blood-brain barrier disruption in a model of sepsis-associated encephalopathy, linking prostaglandin-related neuroinflammation to barrier failure.
How does DPEP2 suppress hyperinflammation?
DPEP2 suppresses hyperinflammation via metabolic reprogramming of macrophages in sepsis, indirectly constraining prostaglandin-driven pathology.
Conclusion
GO:0032307, negative regulation of prostaglandin secretion, captures the cellular brakes that limit prostaglandin release and thereby shape inflammation resolution, immune competence, vascular integrity, and endocrine function. Experimental evidence from efferocytosis, tumor immunology, sepsis, and islet biology shows that these brakes act through epigenetic reprogramming, COX-2 suppression, transporter control, and receptor feedback. Because the term is defined at the level of regulated release, causal assignment of a gene to GO:0032307 requires perturbation followed by direct measurement of secreted prostaglandins. CRISPR knockout, point-mutation, knock-in, and overexpression models provide the most rigorous path to that assignment and to identifying new therapeutic nodes in inflammatory and immune disease.
References
- 1. Ampomah PB et al.. 2022. Macrophages use apoptotic cell-derived methionine and DNMT3A during efferocytosis to promote tissue resolution.. Nat Metab 4(4):444-457 PMID: 35361955
- 2. Morotti M et al.. 2024. PGE(2) inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function.. Nature 629(8011):426-434 PMID: 38658764
- 3. Kikuchi DS et al.. 2019. Poldip2 mediates blood-brain barrier disruption in a model of sepsis-associated encephalopathy.. J Neuroinflammation 16(1):241 PMID: 31779628
- 4. Lambert-Langlais S et al.. 2009. Aldo keto reductase 1B7 and prostaglandin F2alpha are regulators of adrenal endocrine functions.. PLoS One 4(10):e7309 PMID: 19809495
- 5. Mishra A et al.. 2024. Astrocyte Regulation of Cerebral Blood Flow in Health and Disease.. Cold Spring Harb Perspect Biol 16(4) PMID: 38316553
- 6. Watanabe T et al.. 1996. Positive and negative regulation of cell proliferation through prostaglandin receptors in NIH-3T3 cells.. J Cell Physiol 169(2):401-9 PMID: 8908208
- 7. Luo W et al.. 2026. DPEP2 suppresses hyperinflammation via metabolic reprogramming of macrophages in sepsis.. Nat Commun 17(1) PMID: 41803155
- 8. Robertson RP. 1998. Dominance of cyclooxygenase-2 in the regulation of pancreatic islet prostaglandin synthesis.. Diabetes 47(9):1379-83 PMID: 9726224
